uk 68798 has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banchs, JE; Baquero, GA; Depalma, S; Gonzalez, MD; Naccarelli, GV; Penny-Peterson, ED; Samii, SM; Wolbrette, DL; Young, SK | 1 |
| Bavikati, V; Langberg, J; Lloyd, MS; Manocha, P | 1 |
2 other study(ies) available for uk 68798 and Coronary Artery Disease
| Article | Year |
|---|---|
Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Coronary Artery Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Dose-Response Relationship, Drug; Electric Countershock; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Phenethylamines; Recurrence; Stroke Volume; Sulfonamides; Tachycardia, Ventricular; Treatment Outcome; Ventricular Fibrillation; Ventricular Function, Left | 2012 |
Coronary artery disease potentiates response to dofetilide for rhythm control of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Drug Synergism; Female; Georgia; Humans; Male; Middle Aged; Phenethylamines; Prevalence; Sulfonamides; Treatment Outcome | 2012 |